Olanzapine-Samidorphan
Schizoaffective Disorder
Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
New York State Psychiatric Institute
Modality
unclassified
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06740890CT.gov Exercise and Olanzapine-samidorphan | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Schizoaffective Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Olanzapine-Samidorphan (this asset) | New York State Psychiatric Institute | Approved | BB · 65 |
| Paliperidone | Luye Pharma Group Ltd. | P4 | BBB |
| Risperidone | Lyndra Inc. | P4 | BBB |
| Lurasidone | University of Texas Southwestern Medical Center | P4 | BBB |
| Raloxifene | Iris Sommer | P4 | BBB |
| Quetiapine | Otsuka Pharmaceutical Development & Commercialization, Inc. | P4 | BBB |
| Olanzapine | The Royal Ottawa Mental Health Centre | P4 | BBB |
| Dexmedetomidine | BioXcel Therapeutics Inc | P4 | BBB |
| Ziprasidone | Centre for Addiction and Mental Health | P4 | BBB |
+42 more in the Schizoaffective Disorder cohort
Other indications for Olanzapine-Samidorphan
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Schizophrenia | — | P4 | BBB · 72 |
| Bipolar Disorder | — | P4 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Olanzapine-Samidorphan in Schizoaffective Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/olanzapine-samidorphan-schizoaffective-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →